Skip to content
← Back to browse
LIVER Publication-derived

Hepatoblastoma Tumor Organoid Establishment and Characterization

Source Kluiver et al., 2024 · Princess Máxima Center for Pediatric Oncology · 10.1038/s41467-024-52757-w

👤 Thomas A. Kluiver, Yuyan Lu, Stephanie A. Schubert, Lianne J. Kraaier, Femke Ringnalda, Philip Lijnzaad, Jeff DeMartino, Wouter L. Megchelenbrink, Vicky Amo-Addae, Selma Eising, Flavia W. de Faria, Daniel Münter, Marc van de Wetering, Kornelius Kerl, Evelien Duiker, Marius C. van den Heuvel, Vincent E. de Meijer, Ruben H. de Kleine, Jan J. Molenaar, Thanasis Margaritis, Hendrik G. Stunnenberg, Ronald R. de Krijger, József Zsiros, Hans Clevers, Weng Chuan Peng ⏱ 10 days 📋 5 phases 🧫 Patient-Derived Hepatoblastoma

Abstract

This protocol describes the establishment and molecular characterization of patient-derived hepatoblastoma tumor organoids (HBTOs) from biopsies and surgical resections. The organoids recapitulate the molecular heterogeneity of hepatoblastomas (fetal and embryonal subtypes) and enable high-throughput drug screening to identify therapeutic vulnerabilities, including sensitivity to HDAC, FGFR, and EGFR inhibitors.

Cell source
Patient-Derived Hepatoblastoma
Application
Disease modeling and drug screening

Protocol overview

32 steps across 5 phases

Tissue Dissociation and Single Cell Preparation Day 0
  1. 1 Tissue Mincing
  2. 2 Liver Perfusion Medium Incubation
  3. 3 Wash and Centrifuge
  4. 4 Enzymatic Digestion
  5. 5 Assess Dissociation Progress
  6. 6 Mechanical Dissociation
  7. 7 Red Blood Cell Lysis (Optional)
  8. 8 Enzyme Wash-off
Organoid Plating and Initial Culture Day 0–Day 7
  1. 1 Basement Membrane Extract (BME) Preparation
  2. 2 Culture Plate Preparation
  3. 3 Droplet Plating
  4. 4 BME Gelation
  5. 5 Culture Medium Addition
  6. 6 Initial Incubation
Ongoing Organoid Culture and Maintenance Day 7 onwards
  1. 1 Medium Replacement Schedule
  2. 2 Monitor Organoid Morphology
  3. 3 Passage Organoids (Every 1–3 weeks)
  4. 4 Dispase-mediated BME Dissociation
  5. 5 PBS Wash
  6. 6 Single-Cell Dissociation with TryPLE
  7. 7 Final PBS Wash
  8. 8 Replating in Fresh BME
Full Culture Medium Composition and Optimization Ongoing
  1. 1 Full Medium Preparation
  2. 2 Add Basal Supplements
  3. 3 Add Growth Factors
  4. 4 Add Small Molecule Regulators
  5. 5 Reduced Medium Alternative
Validation and Quality Control Upon establishment and at passages P2, P5, P10
  1. 1 CTNNB1 Mutation Verification
  2. 2 Western Blot for β-Catenin
  3. 3 Copy Number Variation (CNV) Profiling
  4. 4 Single-Cell RNA-Seq (scRNA-seq) Characterization
  5. 5 Immunofluorescence (IF) Staining for HNF4A and LEF1

Full SOP

🔬

Create a free account to access this protocol

Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.

Create free account

Already registered? Log in

Attribution

This SOP was authored by Organthis based on the published method in Kluiver et al., 2024. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.

This wording is awaiting legal review.

Something wrong with this entry? Report an issue with this protocol

Need a commercial licence?
Use this protocol in your therapeutic or diagnostic pipeline.
Request Commercial Licence